Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680073d8de7cd-trace').style.display = (document.getElementById('cakeErr680073d8de7cd-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr680073d8de7cd-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680073d8de7cd-code').style.display = (document.getElementById('cakeErr680073d8de7cd-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr680073d8de7cd-context').style.display = (document.getElementById('cakeErr680073d8de7cd-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr680073d8de7cd-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr680073d8de7cd-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 1685,
		&#039;title&#039; =&gt; &#039;Will India-EU deal make drugs dearer? by Rema Nagarajan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a fear being expressed by civil society groups in the developing world. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India&#039;s flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, &lt;a href=&quot;../articles.php?articleId=51&quot;&gt;Access to Medicines and Poverty-Related Diseases&lt;/a&gt; to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &amp;ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &amp;ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The group expressed regret at the way the FTA being negotiated was against the EU&#039;s averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.&lt;/font&gt;
&lt;/p&gt;
&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 2 April, 2010, http://timesofindia.indiatimes.com/india/Will-India-EU-deal-make-drugs-dearer/articleshow/5861723.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 1763,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 1685,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Will India-EU deal make drugs dearer? by Rema Nagarajan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;



Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a fear being expressed by civil society groups in the developing world. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India&#039;s flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, &lt;a href=&quot;https://im4change.in/articles.php?articleId=51&quot; title=&quot;https://im4change.in/articles.php?articleId=51&quot;&gt;Access to Medicines and Poverty-Related Diseases&lt;/a&gt; to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &amp;ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &amp;ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The group expressed regret at the way the FTA being negotiated was against the EU&#039;s averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.&lt;/font&gt;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 1685,
	&#039;title&#039; =&gt; &#039;Will India-EU deal make drugs dearer? by Rema Nagarajan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a fear being expressed by civil society groups in the developing world. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India&#039;s flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, &lt;a href=&quot;../articles.php?articleId=51&quot;&gt;Access to Medicines and Poverty-Related Diseases&lt;/a&gt; to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &amp;ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &amp;ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The group expressed regret at the way the FTA being negotiated was against the EU&#039;s averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.&lt;/font&gt;
&lt;/p&gt;
&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 2 April, 2010, http://timesofindia.indiatimes.com/india/Will-India-EU-deal-make-drugs-dearer/articleshow/5861723.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 1763,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 1685
$metaTitle = &#039;LATEST NEWS UPDATES | Will India-EU deal make drugs dearer? by Rema Nagarajan&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;



Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a...&#039;
$disp = &#039;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a fear being expressed by civil society groups in the developing world. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India&#039;s flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, &lt;a href=&quot;https://im4change.in/articles.php?articleId=51&quot; title=&quot;https://im4change.in/articles.php?articleId=51&quot;&gt;Access to Medicines and Poverty-Related Diseases&lt;/a&gt; to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &amp;ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &amp;ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The group expressed regret at the way the FTA being negotiated was against the EU&#039;s averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.&lt;/font&gt;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Will India-EU deal make drugs dearer? by Rema Nagarajan | Im4change.org</title>
    <meta name="description" content="



Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That's a..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Will India-EU deal make drugs dearer? by Rema Nagarajan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p align="justify"><font ></font></p><p align="justify"><font >Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That's a fear being expressed by civil society groups in the developing world. </font></p><p align="justify"><font >Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India's flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. </font></p><p align="justify"><font >A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, <a href="https://im4change.in/articles.php?articleId=51" title="https://im4change.in/articles.php?articleId=51">Access to Medicines and Poverty-Related Diseases</a> to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. </font></p><p align="justify"><font >The group expressed regret at the way the FTA being negotiated was against the EU's averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. </font></p><p align="justify"><font >This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. </font></p><p align="justify"><font >These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. </font></p><p align="justify"><font >The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. </font></p><p align="justify"><font >Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. </font></p><p align="justify"><font >The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.</font></p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680073d8de7cd-trace').style.display = (document.getElementById('cakeErr680073d8de7cd-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr680073d8de7cd-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680073d8de7cd-code').style.display = (document.getElementById('cakeErr680073d8de7cd-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr680073d8de7cd-context').style.display = (document.getElementById('cakeErr680073d8de7cd-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr680073d8de7cd-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr680073d8de7cd-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 1685,
		&#039;title&#039; =&gt; &#039;Will India-EU deal make drugs dearer? by Rema Nagarajan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a fear being expressed by civil society groups in the developing world. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India&#039;s flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, &lt;a href=&quot;../articles.php?articleId=51&quot;&gt;Access to Medicines and Poverty-Related Diseases&lt;/a&gt; to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &amp;ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &amp;ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The group expressed regret at the way the FTA being negotiated was against the EU&#039;s averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.&lt;/font&gt;
&lt;/p&gt;
&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 2 April, 2010, http://timesofindia.indiatimes.com/india/Will-India-EU-deal-make-drugs-dearer/articleshow/5861723.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 1763,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 1685,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Will India-EU deal make drugs dearer? by Rema Nagarajan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;



Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a fear being expressed by civil society groups in the developing world. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India&#039;s flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, &lt;a href=&quot;https://im4change.in/articles.php?articleId=51&quot; title=&quot;https://im4change.in/articles.php?articleId=51&quot;&gt;Access to Medicines and Poverty-Related Diseases&lt;/a&gt; to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &amp;ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &amp;ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The group expressed regret at the way the FTA being negotiated was against the EU&#039;s averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.&lt;/font&gt;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 1685,
	&#039;title&#039; =&gt; &#039;Will India-EU deal make drugs dearer? by Rema Nagarajan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a fear being expressed by civil society groups in the developing world. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India&#039;s flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, &lt;a href=&quot;../articles.php?articleId=51&quot;&gt;Access to Medicines and Poverty-Related Diseases&lt;/a&gt; to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &amp;ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &amp;ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The group expressed regret at the way the FTA being negotiated was against the EU&#039;s averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.&lt;/font&gt;
&lt;/p&gt;
&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 2 April, 2010, http://timesofindia.indiatimes.com/india/Will-India-EU-deal-make-drugs-dearer/articleshow/5861723.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 1763,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 1685
$metaTitle = &#039;LATEST NEWS UPDATES | Will India-EU deal make drugs dearer? by Rema Nagarajan&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;



Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a...&#039;
$disp = &#039;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a fear being expressed by civil society groups in the developing world. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India&#039;s flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, &lt;a href=&quot;https://im4change.in/articles.php?articleId=51&quot; title=&quot;https://im4change.in/articles.php?articleId=51&quot;&gt;Access to Medicines and Poverty-Related Diseases&lt;/a&gt; to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &amp;ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &amp;ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The group expressed regret at the way the FTA being negotiated was against the EU&#039;s averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.&lt;/font&gt;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Will India-EU deal make drugs dearer? by Rema Nagarajan | Im4change.org</title>
    <meta name="description" content="



Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That's a..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Will India-EU deal make drugs dearer? by Rema Nagarajan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p align="justify"><font ></font></p><p align="justify"><font >Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That's a fear being expressed by civil society groups in the developing world. </font></p><p align="justify"><font >Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India's flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. </font></p><p align="justify"><font >A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, <a href="https://im4change.in/articles.php?articleId=51" title="https://im4change.in/articles.php?articleId=51">Access to Medicines and Poverty-Related Diseases</a> to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. </font></p><p align="justify"><font >The group expressed regret at the way the FTA being negotiated was against the EU's averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. </font></p><p align="justify"><font >This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. </font></p><p align="justify"><font >These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. </font></p><p align="justify"><font >The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. </font></p><p align="justify"><font >Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. </font></p><p align="justify"><font >The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.</font></p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680073d8de7cd-trace').style.display = (document.getElementById('cakeErr680073d8de7cd-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr680073d8de7cd-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680073d8de7cd-code').style.display = (document.getElementById('cakeErr680073d8de7cd-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr680073d8de7cd-context').style.display = (document.getElementById('cakeErr680073d8de7cd-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr680073d8de7cd-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr680073d8de7cd-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 1685,
		&#039;title&#039; =&gt; &#039;Will India-EU deal make drugs dearer? by Rema Nagarajan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a fear being expressed by civil society groups in the developing world. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India&#039;s flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, &lt;a href=&quot;../articles.php?articleId=51&quot;&gt;Access to Medicines and Poverty-Related Diseases&lt;/a&gt; to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &amp;ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &amp;ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The group expressed regret at the way the FTA being negotiated was against the EU&#039;s averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.&lt;/font&gt;
&lt;/p&gt;
&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 2 April, 2010, http://timesofindia.indiatimes.com/india/Will-India-EU-deal-make-drugs-dearer/articleshow/5861723.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 1763,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 1685,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Will India-EU deal make drugs dearer? by Rema Nagarajan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;



Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a fear being expressed by civil society groups in the developing world. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India&#039;s flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, &lt;a href=&quot;https://im4change.in/articles.php?articleId=51&quot; title=&quot;https://im4change.in/articles.php?articleId=51&quot;&gt;Access to Medicines and Poverty-Related Diseases&lt;/a&gt; to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &amp;ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &amp;ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The group expressed regret at the way the FTA being negotiated was against the EU&#039;s averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.&lt;/font&gt;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 1685,
	&#039;title&#039; =&gt; &#039;Will India-EU deal make drugs dearer? by Rema Nagarajan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a fear being expressed by civil society groups in the developing world. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India&#039;s flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, &lt;a href=&quot;../articles.php?articleId=51&quot;&gt;Access to Medicines and Poverty-Related Diseases&lt;/a&gt; to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &amp;ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &amp;ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The group expressed regret at the way the FTA being negotiated was against the EU&#039;s averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. &lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.&lt;/font&gt;
&lt;/p&gt;
&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 2 April, 2010, http://timesofindia.indiatimes.com/india/Will-India-EU-deal-make-drugs-dearer/articleshow/5861723.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 1763,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 1685
$metaTitle = &#039;LATEST NEWS UPDATES | Will India-EU deal make drugs dearer? by Rema Nagarajan&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;



Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a...&#039;
$disp = &#039;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That&#039;s a fear being expressed by civil society groups in the developing world. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India&#039;s flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, &lt;a href=&quot;https://im4change.in/articles.php?articleId=51&quot; title=&quot;https://im4change.in/articles.php?articleId=51&quot;&gt;Access to Medicines and Poverty-Related Diseases&lt;/a&gt; to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &amp;ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &amp;ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The group expressed regret at the way the FTA being negotiated was against the EU&#039;s averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. &lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.&lt;/font&gt;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Will India-EU deal make drugs dearer? by Rema Nagarajan | Im4change.org</title>
    <meta name="description" content="



Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That's a..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Will India-EU deal make drugs dearer? by Rema Nagarajan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p align="justify"><font ></font></p><p align="justify"><font >Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That's a fear being expressed by civil society groups in the developing world. </font></p><p align="justify"><font >Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India's flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. </font></p><p align="justify"><font >A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, <a href="https://im4change.in/articles.php?articleId=51" title="https://im4change.in/articles.php?articleId=51">Access to Medicines and Poverty-Related Diseases</a> to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. </font></p><p align="justify"><font >The group expressed regret at the way the FTA being negotiated was against the EU's averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. </font></p><p align="justify"><font >This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. </font></p><p align="justify"><font >These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. </font></p><p align="justify"><font >The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. </font></p><p align="justify"><font >Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. </font></p><p align="justify"><font >The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.</font></p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 1685,
		'title' => 'Will India-EU deal make drugs dearer? by Rema Nagarajan',
		'subheading' => '',
		'description' => '<p align="justify">
<font face="arial,helvetica,sans-serif" size="3"></font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That's a fear being expressed by civil society groups in the developing world. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India's flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, <a href="../articles.php?articleId=51">Access to Medicines and Poverty-Related Diseases</a> to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">The group expressed regret at the way the FTA being negotiated was against the EU's averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.</font>
</p>
',
		'credit_writer' => 'The Times of India, 2 April, 2010, http://timesofindia.indiatimes.com/india/Will-India-EU-deal-make-drugs-dearer/articleshow/5861723.cms',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 1763,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 1685,
	'metaTitle' => 'LATEST NEWS UPDATES | Will India-EU deal make drugs dearer? by Rema Nagarajan',
	'metaKeywords' => 'Health',
	'metaDesc' => '



Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That's a...',
	'disp' => '<p align="justify"><font ></font></p><p align="justify"><font >Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That's a fear being expressed by civil society groups in the developing world. </font></p><p align="justify"><font >Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India's flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. </font></p><p align="justify"><font >A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, <a href="https://im4change.in/articles.php?articleId=51" title="https://im4change.in/articles.php?articleId=51">Access to Medicines and Poverty-Related Diseases</a> to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. </font></p><p align="justify"><font >The group expressed regret at the way the FTA being negotiated was against the EU's averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. </font></p><p align="justify"><font >This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. </font></p><p align="justify"><font >These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. </font></p><p align="justify"><font >The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. </font></p><p align="justify"><font >Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. </font></p><p align="justify"><font >The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.</font></p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 1685,
	'title' => 'Will India-EU deal make drugs dearer? by Rema Nagarajan',
	'subheading' => '',
	'description' => '<p align="justify">
<font face="arial,helvetica,sans-serif" size="3"></font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That's a fear being expressed by civil society groups in the developing world. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India's flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, <a href="../articles.php?articleId=51">Access to Medicines and Poverty-Related Diseases</a> to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">The group expressed regret at the way the FTA being negotiated was against the EU's averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. </font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.</font>
</p>
',
	'credit_writer' => 'The Times of India, 2 April, 2010, http://timesofindia.indiatimes.com/india/Will-India-EU-deal-make-drugs-dearer/articleshow/5861723.cms',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'will-india-eu-deal-make-drugs-dearer-by-rema-nagarajan-1763',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 1763,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 1685
$metaTitle = 'LATEST NEWS UPDATES | Will India-EU deal make drugs dearer? by Rema Nagarajan'
$metaKeywords = 'Health'
$metaDesc = '



Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That's a...'
$disp = '<p align="justify"><font ></font></p><p align="justify"><font >Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That's a fear being expressed by civil society groups in the developing world. </font></p><p align="justify"><font >Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India's flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. </font></p><p align="justify"><font >A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, <a href="https://im4change.in/articles.php?articleId=51" title="https://im4change.in/articles.php?articleId=51">Access to Medicines and Poverty-Related Diseases</a> to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions &ndash; such as data exclusivity, patent term extensions and enforcement of IP rights and border measures &ndash; that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. </font></p><p align="justify"><font >The group expressed regret at the way the FTA being negotiated was against the EU's averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. </font></p><p align="justify"><font >This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. </font></p><p align="justify"><font >These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. </font></p><p align="justify"><font >The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. </font></p><p align="justify"><font >Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. </font></p><p align="justify"><font >The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.</font></p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Will India-EU deal make drugs dearer? by Rema Nagarajan

Is the Indian government bargaining away the rights of millions across the world to essential drugs supplied by India, hailed as the pharmacy of the developing world, in the name of free trade with the European Union (EU)? That's a fear being expressed by civil society groups in the developing world. Commerce minister Anand Sharma vehemently denies such a possibility, claiming that the free trade agreement (FTA) under negotiation with the EU will not harm India's flourishing pharmaceuticals industry, but voices from within the European Parliament belie his assertions. A letter, dated April 22, from the recently established working group in the European Parliament on Innovation, Access to Medicines and Poverty-Related Diseases to the European commissioner for international trade, expressed concern that the EU-India FTA may contain provisions – such as data exclusivity, patent term extensions and enforcement of IP rights and border measures – that reverse the advances made on access to medicines, which could have dire consequences for patients in India and in the rest of the developing world. The group expressed regret at the way the FTA being negotiated was against the EU's averred commitment to placing public health protection over commercial interests. The letter urged the commissioner to ensure that the negotiations on behalf of the EU did not contain clauses that went beyond the requirements of the trade-related intellectual property rights (TRIPS) agreement under the WTO. This letter has come close on the heel of representations from several civil society groups from developing countries across Africa, Asia and South America, including Brazil and Thailand, dependent on India for their supply of affordable high quality generic drugs, including crucial HIV/AIDS drugs. These countries have expressed the fear that Europe is pushing India to impose greater intellectual property protection on medicines, measures which would delay the registration and marketing of generic medicines, and would extend the duration of a patent, blocking competition and keeping the price of medicines out of the reach of patients. None of this is required under WTO or the TRIPS agreement. India began granting patents on medicines from 2005 in keeping with the agreement, but the government was careful to include measures to limit abusive patenting and protect public health. The working group on intellectual property of the Brazilian Network for the Integration of People further points out that Indian generic versions play an important role in price negotiations in the world and are also key to promoting price competition and broader access to treatment in developing countries. Despite these negotiations having such far-reaching consequences, there have been no consultations with civil society and other stakeholders like farmers and patients. Trade negotiations between the EU and India have been going on since 2007 and both sides hope to conclude the agreement by October this year. A meeting for this purpose will be held in Brussels next week. For over two years, civil society groups have been protesting the hush-hush manner in which the rights of millions to essential drugs is being bargained away without even the draft document being available to the public. The Delhi Network of Positive People, a support group of people living with HIV/AIDS, has accused the government of keeping even Parliament in the dark about the negotiations and its implications, which could undermine the public health safeguards Parliament built into the Indian patent law. Public health groups across the world have expressed the hope that India would demonstrate its commitment to patients over profit starting with opening up the negotiations to public scrutiny.